Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer

Summary

Cancer associated fibroblasts (CAFs) can promote tumor cell proliferation, migration, invasion, and angiogenesis through immunosuppressive effects and the production of mediators, thereby promoting tumor growth and progression. The characteristic of CAFs is high expression of fibroblast activation protein (FAP). In approximately 90% of epithelial derived tumors, FAP is highly overexpressed on the membrane of CAFs. Contrary to CAFs, FAP expression is lower or absent in normal tissues. Therefore, FAP inhibitors (FAPI) targeting FAP can overcome the limitations of 18F-2-fluoro.2-deoxy-D-glucose fluorodeoxyglucose(18F-FDG) PET imaging. But like 18F-FDG, wound healing, fibrosis, and inflammation can also uptake FAPI.. Therefore, a comparison of the performance of 18F-FDG and 18F-FAPI PET imaging in diagnosing primary and metastatic lesions of various types of cancer is conducted to evaluate the potential value of these new radiopharmaceuticals as effective alternatives to 18F-FDG, highlighting their advantages and limitations.

Eligibility

Inclusion Criteria:

1. Adult patients (≥ 18 years old);
2. Suspected or newly diagnosed malignant tumor patients;
3. Patients who underwent 18F-FDG and 18F-FAPI PET scans within one week;
4. Patients who are able to provide informed consent forms (signed by participants, parents, or legal representatives) and consent forms in accordance with the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

1. Pregnant women;
2. Scanned images with poor image quality due to factors such as body movement;
3. Patients with mental illness or other unsuitable conditions for examination, poor compliance, etc.

Conditions1

Browse More Trials